1. Home
  2. TTRX vs XGN Comparison

TTRX vs XGN Comparison

Compare TTRX & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$3.60

Market Cap

116.0M

Sector

Health Care

ML Signal

N/A

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$3.04

Market Cap

74.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTRX
XGN
Founded
2015
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.0M
74.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
TTRX
XGN
Price
$3.60
$3.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$8.00
$9.14
AVG Volume (30 Days)
14.1K
315.5K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$20.99
Revenue Next Year
N/A
$11.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$2.96
52 Week High
$5.98
$12.23

Technical Indicators

Market Signals
Indicator
TTRX
XGN
Relative Strength Index (RSI) 48.74 31.44
Support Level $3.55 N/A
Resistance Level $4.01 $4.00
Average True Range (ATR) 0.22 0.31
MACD 0.04 0.02
Stochastic Oscillator 41.18 6.78

Price Performance

Historical Comparison
TTRX
XGN

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: